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XR-NTX acceptability and interest in opioid agonist treatments.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).Fig. 1. Study design.1. Introduction
The dramatic growth in the U.S. inmate population over the
last three decades has resulted from the increased detention of
individuals for drug-related offenses and recidivist offenders.
As a result, those with substance use disorders (SUDs) with or
at risk for HIV infection are concentrated within the criminal
justice system (CJS). The prevalence of HIV and AIDS is 3-
and 4-fold greater, respectively, among incarcerated persons
compared to the general population [1,2]. In 2004, the U.S.
Department of Justice reported that 53% of state prisoners met
DSM-IV criteria for drug abuse or dependence, 56% reported
regular use in the month prior to their offence, specifically,
13.1% reported using heroin and opiates [3,4]. In a study
conducted in CT, amongHIV-infected prisoners with SUDs, 61%
met criteria for opioid dependence [5–8].
The revolving door of prisons and jails results in 12 million
people being released annually to communities, oftentimes
with undiagnosed or untreated medical conditions [9]; includ-
ing one-sixth of the nearly 1.2 million people living with HIV/
AIDS (PLWH) [2]. Though HIV-infected prisoners markedly
reduceHIV-1 RNA levels and achievemarkedly high levels viral
suppression (VS) during incarceration due to the availability of
combination antiretroviral therapy (cART) and the structure of
the facilities [10–12], these benefits are lost soon after release
[10,13,14], especially due to drug and alcohol relapse [15],
especially heroin. The negative consequences of opioid relapse
for HIV-infected patients include poor retention in care
[14,16–18], cART adherence [5,6] and increased recidivism to
prison/jail [19,20]. This is in addition to the increased early
mortality risk upon release [21–27], mostly associated with
opioid overdose [22,25–27], affirms the need for evidence-
based transitional interventions.
According to the International Association of Physicians in
AIDS Care (IAPAC) guidelines, only directly administered anti-
retroviral therapy (DAART) is effective for transitioning HIV-
infected prisoners [28]. One randomized controlled trial (RCT)
of DAART for released prisoners, however, showed that for the
subset meeting criteria for opioid dependence, those retained
on buprenorphine post-release markedly increased their like-
lihood of achieving VS [7,8], suggesting that medication-
assisted therapies (MATs) might be a more effective and less
costly strategy for released prisoners with HIV and opioid
dependence. Despite there being three FDA-approved phar-
macological treatments for opioid dependence, methadone
(MMT), buprenorphine (BMT) and extended-release naltrex-
one (XR-NTX), with rare exception, have they not been empir-
ically tested as transitional care for released prisoners [29–33].
Despite preliminary successes using MAT among HIV seroneg-
ative subjects [31,32,34,35], these treatments have not been
deployed systematicallywithin the CJS [36–39] nor deployed to
optimize HIV treatment, as recommended by the IAPAC for
PLWH and SUDs in the community[28].
As part on the National Institute of Drug Abuse's (NIDA)
initiative to examine the impact of the seek, test, treat, andretain model of care (STTR) for criminal justice populations
[40], this study directly examines the ability of XR-NTX to
effectively “treat and retain” opioid dependent prisoners
through the post-release transitional period. To test whether
XR-NTX effectively stabilizes patients through this precarious
post-release period, we have implemented a novel double-
blind, placebo-controlled RCT of XR-NTX among opioid depen-
dent HIV-infected prisoners and jail detainees transitioning to
the community,with anexamination of bothHIV and substance
abuse treatment outcomes.2. Methods
2.1. Study design
Project NEW HOPE (Needing Extended-release Wellness
Helping Opioid dependent People Excel) is a multi-site, double-
blind, placebo-controlled RCT of XR-NTX among opioid depen-
dent HIV-infected prisoners and jail detainees transitioning to
the community. The study design is shown in Fig. 1.
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Institutional Review Boards (IRB) at Yale University,
Waterbury Hospital and Baystate Medical Center, and research
committees at Hampden County Correctional Centers (HCCC)
and the Connecticut Department of Correction (CTDOC)
reviewed and approved all study procedures. The study is
registered at www.clinicaltrials.gov (NCT01246401). Addition-
al protections were provided by the Office of Human Research
Protections (OHRP) at the Department of Health and Human
Services and a Certificate of Confidentiality (CoC)was obtained.
2.3. Research goals
Given the high rate of relapse to opioid use upon release [41]
and its association with poor HIV treatment outcomes [15,42],
this study's aim is to examine if using an evidence-based treat-
ment for opioid dependence improves HIV and substance abuse
treatment outcomes in the post-release period. Outcomes
include HIV-related outcomes (HIV-1 RNA levels, including VS,
CD4 count, cART adherence, retention in HIV care); substance
abuse outcomes (time to opioid relapse, percent of opioid
negative urine screens, opioid craving); recidivism and re-
arrests; adverse side effects; andHIV risk behaviors (sexual and
drug-related risks). The primary outcome is the proportion
achieving VS (HIV-1 RNA b 400 copies/mL) 6 months post-
release. Additional detail regarding the outcomes of interest can
be found in the Analytical Plan section.
2.4. Sample size and power calculations
Sample size calculations were based on the primary out-
come of the proportion of participants who achieve VS
6 months after release, based on 2:1 randomization; increased
allocation to the XR-NTX armwas justified to assess for adverse
side effects. Sample size requirements for a Type I error rate of
0.05 and power of 80% estimated by preliminary data from our
prison-release data suggest that approximately 60% of inmates
leave prison with VS [10]. Of note, more recent data suggest
that VS upon release is 70% [12]. Using an intention-to-treat
(ITT) analysis and assuming a baseline VS of 60% [10], 150
subjects would be required to a difference of 25% between the
two treatment arms if randomized 2:1 (XR-NTX = 100 and
placebo = 50).
3. Study procedures
3.1. Recruitment and screening
Recruitment started in 2011 and will continue until 2015 in
all prisons and jails by Infectious Disease Nurses (IDN), who
coordinate all HIV-related care for HIV-infected inmates. Initial
study criteria includes: 1) being HIV-seropositive; 2) returning
to three sites in Connecticut (New Haven, Hartford, Waterbury
[2012 and 2013 only] or Massachusetts (Springfield only);
3)meetsDSM-IV criteria for opioiddependence (using theRapid
Opioid Dependency Scale) based on information 12 months
prior to their current incarceration [43]; 4) able to provide
informed consent; 5) speaks English or Spanish; and 6) 18 years
or older. Those meeting screening criteria were asked to sign a
release of information (ROI) so that research staff can meet andinform them about the research study and undergo informed
consent procedures. For PLWH and released to the community
without being assessed, referrals from the community were
allowed from HIV clinicians and drug treatment providers, case
managers and through self-referrals using approved flyers
and advertisements if made within 30 days of release to the
community.
3.2. Eligibility process
After receiving the ROI, Research Staff scheduled an ap-
pointment with the inmate in a confidential setting to assess
additional eligibility criteria. If the inmate was eligible for the
study, the study staff member described the study and enrolled
the participant. Additional inclusion criteria include: 1) not
participating in a pharmacotherapy or adherence trial in the
previous 30 days; and 2) within 30 days of release from prison
or jail. Exclusion criteria included: 1) threatening behavior to-
ward study staff or other participants; 2) pending federal
charges; 3) prescription of opioid pain medications or express-
ing a need for them; 4) known hypersensitivity to naltrexone,
PLG (polylactide-co-glycolide), arboxymethylcellulose, or any
other components of the diluent; and 5) medication contrain-
dications that included: a) already enrolled in an opioid substi-
tution therapy program; b) aspartate aminotransferase (AST)
or alanine aminotransferase (ALT) elevations (N5× upper limit
of normal); c) evidence of Child Pugh Class C cirrhosis; or
d) breastfeeding, pregnant or unwilling to use contraception
(women).
3.3. Informed consent and enrollment
Upon completion of eligibility determination, the study
researchmember completed informed consent procedures and
assessed the participant's willingness to enroll in the study,
including receiving six monthly injections, where the first was
administered approximately 7 days prior to release and then
attend monthly interviews over twelve months post-release.
To ensure that there was no real or perceived coercion for
enrollment during incarceration, all participants underwent a
second written informed consent process upon release from
the correctional facility to confirm their interest in study par-
ticipation. For those that were referred from the community or
were released unexpectedly, the initial injection was adminis-
tered at the study sites after completing the baseline interview
and medical chart review.
4. Covariate and outcome measures
4.1. Screening and intervention measures
After informed consent completion, all enrolled participants
underwent baseline assessments, follow-up interviews and
laboratory assessments monthly for 12 months. Please refer to
Table 1 for the measures, main outcomes assessed, and the
study timeline.
4.2. Process measures
In addition to the measures noted in Table 1, qualitative
information was assessed to address:
Table 1
Study activity and measures.
Study activity Study time point in months from day of release from incarceration
−3 −1 week 0 1 2 3 4 5 6 7 8 9 10 11 12
Study activity
Screening for Eligibility X
Medical Chart Review X
Randomization X
Injection and Clinical Interview X X X X X X
Research Interview X X X X X X X X X X X X X X
Demographic information
Demographic Questions⁎ X
Housing Questions⁎ X X X X X X X X X X X X X X
Health care status
HIV quality of life (SF-12)⁎ [71] X X X X X
Current Medications X X X X X X X X X X X X X X
Prescription Reﬁll X X X X X X X X X X X X X X
Prison Medical Record (Medication, cART regimen,
HCV antibody, medication allergies)
X
Visual Analog Scale [51] X X X X X X X X X X X X X X
Previous Experience with Alcohol and Drug Treatment X
Mental health
Mini International Neuropsychiatric Interview
(MINI)⁎ [72–74]
X
Correctional Medical Record Diagnoses X
Brief Symptom Inventory-18 (BSI-18) [75–77] X X X X X
Drug and alcohol use
Rapid Opioid Dependence Screen [43] X
Addiction Severity Index Lite⁎ [78–80] X X X X X
Drug Urine Toxicology Screening X X X X X X X X X X X X X X
Alcohol Use Disorder Identiﬁcation Test⁎ [54,81–82] X
Timeline Recall [83,84] X X X X X X X X X X X X X X
Opioid Craving X X X X X X X X X X X X X X X
DSM-IV Criteria using MINI [73] X
Blood Alcohol Content via Breathalyzer X X X X X X X X X X X X X
HIV risk behaviors
Sexual Risk Behaviors⁎ [85] X X X X X X X X X X X X X X
HIV biological outcome measures
HIV-1 RNA level⁎ X X X X X
CD4 Count⁎ X X X X X
HIV genotype⁎ X X
Other laboratory tests
Liver Function Tests (AST, ALT) X X X X X X X
Renal Function Tests (BUN, Creatinine) X X X X X X X
Side effects
Systemic Assessment for Treatment Emergent Effects
Intervention (SAFTEE) [44,86]
X X X X X X X
Payments
Research Interviews⁎⁎ $20 $20 $20 $20 $40 $20 $20 $40 $30 $30 $60 $30 $30 $60
Clinical Interviews⁎⁎ $10 $10 $10 $10 $10 $10
Legend: cART = combination antiretroviral therapy; CJS = criminal justice system; ALT = alanine aminotransferase; AST = aspartate aminotransferase;
BUN = blood urine nitrogen.
⁎ Seek, test, treat & retain harmonized measure.
⁎⁎ Payment for interviews completed in the correctional facilities were paid after release.
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injectable, long-acting opioid dependence treatment
would be acceptable given the other treatments available
in the community, yet not available during incarceration.
Of the initial 199 participants referred to the study, 132
(66%) signed consent forms while still incarcerated. The
main reason for ineligibility was not meeting criteria for
opioid dependence during the screening process (47%)
(Table 2). Of the 132 that signed informed consent
forms, 106 (80%) completed baseline interviews, pro-
viding insight into the acceptability of involvement in
this study and potentially for XR-NTX as an intervention
to prevent relapse (see Fig. 2).(2) Acceptability of opioid antagonist treatment in persons
with experience with opioid agonist treatments and
thus evaluating whether this FDA-approved treatment
will be accepted by those with experience with prior
opioid agonist treatments. Themain reason for refusal in
the different stages of enrollment in this study was a
preference for another form of MAT (34%) (Table 2).
Thus far, 79% (79/100) of the participants in the study
have self-reported previous experience with MMT or
BMT (Fig. 3).
(3) Acceptability of injections by assessing howmany partic-
ipants who agree to participate in the study and com-
plete baseline interviews will actually agree to receive
Table 2
Reasons for refusal or ineligibility of study participation.
Before initial consent
Total not screened 5
Refused screening, does not want treatment 2
Released before being seen 1
Refused without a reason given 1
Not interested in participating a study 1
Total ineligible 34
Does not meet DSM-IV criteria for OD 16
Enrolled in another research study 1
On methadone + refused 1
Will be released out of catchment areas 7
Medical need for pain medication 8
Cirrhosis + refused 1
Total refused 28
Wants another form of treatment 8
Refused to sign consent —may want BMT on release 1
Study fatigue 2
Does not want injections 1
Concerned about current health issues and possible
complications
2
Does not want treatment 2
Afraid of needles and does not want treatment 1
Does not want placebo 2
No reason given/not interested 3
Does not want NTX 1
No reason for refusal + Elevated LFTs 1
Released before consented, wanted to think about it 1
Refused + being released out of area 3
After initial consent, prior to release from prison
Total disenrolled 2
Behavior issues 1
Passed away in prison (unrelated to study/health) 1
Total refused 13
Wants another form of treatment 5
Advised by family not to enroll, released out of area,
possible need pain meds
1
Does not think he needs treatment, and will not be
released early
1
Does not have time, does not need the money 1
Concerned about current health issues doesn't want
complications
1
“I don't want to feel like a lab rat” 1
Refused — no reason given 3
Total ineligible 6
Liver Failure/Elevated LFTs 2
Found to be unable to consent (memory/cognition issues) 1
Cirrhosis, wants methadone & medical need for pain meds 1
On methadone 2
After initial consent, after release from prison
Total lost upon release, reasons missed injections 13
Released too quickly post referral 1
Refused injection in prison, and moved upon release 1
Released to parole unexpectedly 3
Released unexpectedly 8
Total refused 7
Wants another form of treatment 3
Moving out of area 1
Transportation issues 1
No reason given 2
Abbreviations: OD, opioid dependence; BMT, buprenorphine maintenance
treatment; NTX, naltrexone; LFTs, liver function tests.
Referred
199*
Consented
132 (66% of
referred)
Released from
Incarceration
89 (84% of
baselined)
10 Currently
Incarcerated
3 Not Eligible
2 Refused
2 Disenrolled
Completed Baseline
Interviewed
106 (80% of eligible)
26 Did not 
Complete 
Baseline 
Interview
5 Not
Screened
34 Not Eligible
28 Refused
Received First
Injection
65 (73% of
released)
13 Lost at Release
7 Refused
4 Contraindication
*Study is still recruiting.
Fig. 2. Study flow of current acceptability. *Study is still recruiting.
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thosewho have completed baseline interviews 84% (89/
106) were released from incarceration, and 73% (65/89)
received their initial injection near the day of release.
(4) Attrition from intervention, to assess whetherparticipants will remain in the assigned study arm
and adhere to the study medication, thus focusing on
persistence of monthly injections in a placebo-
controlled trial. For participants wishing to switch
to another form of treatment, including but not
limited to another form of MAT or inpatient treat-
ment, s/he will be continuously followed for the
duration of the study but will receive no further
study injections.
(5) Tolerability and adverse event monitoring is assessed by
recording the number and frequency of adverse events
monitored using the Systemic Assessment For Treat-
ment Emergent Effects Intervention (SAFTEE) [44].
(6) Ancillary encounters, are assessed and include additional
services that participantsmay request including clinical/
medical services, counseling and case management
services such as food, shelter, insurance, drug/alcohol
counseling or detoxification, mental illness treatment,
and medical insurance enrollment.
(7) Constant communication with study staff at all study
sites is recorded with CTDOC and HCCC personnel, and
participants.
22%
67%
52%
3%
43%
38%
22% 23%
0%
5%
0%
10%
20%
30%
40%
50%
60%
70%
80%
None Methadone Buprenorphine Oral Naltrexone More than One*
Lifeme Past 30 Days
* also included in each individual MAT
Fig. 3. Previous experience with medication assisted therapy (N = 99).
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All study medication packages (active drug and placebo)
were provided and prepared by Alkermes, Inc. and randomized
and dispensed by the Yale-New Haven Hospital or Baystate
Medical Center Investigational Drug Service (IDS) pharmacists
in a blindedmanner. Participants were randomized 2:1 prior to
their release from the correctional facility by the IDS pharma-
cist, to XR-NTX or placebo. IDS pharmacists stored, distributed
and labeled study medications using participant identification
numbers. To maintain the double-blinded condition of the
study design, placebo microspheres were used instead of
naltrexone, and vials containing the microspheres were tinted
amber to mask the color differences in the solution. To control
for covariates potentially associated with the outcomes, co-
variate adaptive randomizationwas used [45–47]. These covar-
iates included: 1) community release site (greater New Haven,
Hartford, or Springfield areas); and 2) being prescribed or not
prescribed cART.
6. Intervention
6.1. Study procedures
Injections were optimally initiated prior to correctional
release, thereby introducing specific challenges and issues
during the implementation process. These issues are later
described in this paper and in Table 3. After release, participants
are followed for 12 months, receiving an additional 5 injections
and 13 interviews. Please see Table 1 for the study timeline for
study and injection interviews.
(1) Pre-Release: After enrollment, a baseline interview was
completed using a computer-assisted survey instrument
(CASI) [48,49]. To ensure participant confidentiality,
CASI was selected based on our previous prison studies
[50] to allow inmates to respond to sensitive questions
about drug and alcohol use and HIV risk behaviors. See
Table 1 for the list of instruments administered during
the baseline interview. Before final enrollment and the
first injection, a clinical researcher (CR) reviewed the
inmate's medical record to ensure s/he does not haveChild Pugh Class C cirrhosis or other contraindications to
XR-NTX and administered the study medication. In
order to ensure that the correctional facility was aware
of the inmates' enrollment and administration of the
study medication, a sticker and “order” were placed in
the medical chart with a brief summary of the study
drug's possible side effects and the toll-free number to
call should an inmate experience any perceived side
effects. If a participant was released without receiving
an injection prior to release or was referred from the
community, the study medication was administered
within 30 days post-release, including those who
relapsed to opioids before the first injection.
(2) Day of Release: On the expected day of release the
research assistant (RA) met and transported the partic-
ipant to the study site. Additionally, participants com-
pleted a brief interview to document any change in their
health and behaviorswhile theywere in the correctional
facility including study drug injection experience and
potential side effects, aswell as undergoing phlebotomy,
alcohol breathalyzer assessments, drug urine screening,
and update their contact information. To improve re-
tention, participants were paid a “bonus” payment for
showing up immediately after release (see Table 1), and
a RA accompanied the participants to a site of their
preference (home, shelter, short-term housing, etc.) and
inquired about any other local spots where they are
likely to spend time during the course of the study.
(3) Monthly Research Visits: Over 12 months, participants
meet the RA every month for CASI interviews, phlebot-
omy, drug urine screens, urine pregnancy tests for
female participants, alcohol breathalyzer assessments,
and cART adherence assessments using the Visual
Analog Scale (VAS) [51]. During the intervention phase
(6 months) of the study, adverse side effects were
assessed and all participants received a brief 15-minute
medical management (MM) counseling intervention
[52].
(4) Injection Procedures: Following the initial injection, five
total injections are administered, each approximately
28 days apart. At each visit, participants met with a CR
who assessed side effects from the previous injection,
Table 3
Study implementation issues.
Obstacle Action taken Knowledge gained
Harmonized data measures & multisite data transfers
1) Creating interviews using
harmonized data measures
Collaboration with NIDA and 11 additional grantees on
selecting and implementing harmonized measures.
http://www.drugabuse.gov/researchers/research-resources/
data-harmonization-projects/seek-test-treat-retain.
Strong communication and attention to detail was
needed to ensure the correct measures were collected
at the appropriate times. Study participants complained
that surveys were too long.
2) Deidentiﬁcation of data In order to comply with HIPAA regulations, all data were
deidentiﬁed before data transfers to NIDA and from Baystate
to Yale. Yale Information Technology Services (ITS) and
Human Research Protection Program were consulted ensure
all data transfers meet HIPAA regulations.
Prior to data collection, Yale Human Research Protection
Program policies were explored to ensure data collected
for the harmonization was compliant with HIPAA
regulations and ensured that all data to be transferred
was deidentiﬁed as required. Each site maintained a link
between study number and personal identities.
3) Multisite data collection To ensure all data was properly protected, the Yale ITS
encrypted ﬁle transfer was used on a quarterly basis to
transfer data from Baystate Medical Center to Yale AIDS
Program. Once the data was received into the ofﬁce, it
was saved on the Yale secure server.
Collaboration from different departments within Yale
University and updates of new services to safeguard
protected data. Yale ITS and Baystate ITS needed to
ensure that computers and programs were compatible
with encryption software and interview software.
4) Coordination of multiple
review boards and
approval
Upon creation of the study protocol to be submitted,
reviewed and approved by multiple review boards, a review
of the different institutions' policy to reduce the number of
amendments and changes required before approval.
Communication with Yale IRB (as primary site) to assist
with coordination of federal approvals required for this
vulnerable population.
Approval from the primary institution was required
before other approvals were able to be gained.
Communication with the different institutions before
a ﬁnal protocol is submitted is essential to receive the
appropriate approvals in a timely manner. This
resulted in a process that approached 12 months.
Recruitment and facility staff trainings
5) Educational sessions on
medication assisted
therapies
Interactive information sessions were conducted throughout
the study to inform the correctional staff of newly FDA
approved injectable formulation of NTX and of other
pharmacotherapies approved for the treatment of opioid
dependence. Addressing concerns and questions regarding
the different treatments.
Correctional staff was updated and given a refresher
of current treatments for opioid dependence. This
opened another line of communication with the
correctional staff.
Changes in department of corrections policies
6) Methadone Maintenance
Program in two facilities
In CT one of the men's facilities and the women's facility
offered those with a short sentence entering the facility on
a methadone maintenance program to continue during
their incarceration. Additional attention was paid to those
on methadone and some participants became ineligible for
the study. This change went into effect July 2012.
Changes in availability of alternative medication
assisted therapies altered willingness to participate
in the study.
7) XR-NTX initiation and
referral
A pilot program for XR-NTX starting prior to release with
community maintenance was created and made available
for residents with alcohol or opioid addictions in the
addiction treatment facility of the HCCC starting in April
2013. Prior to this, education of staff and residents on
options for medically assisted treatment and community
treatment sites was done in all the HCCC facilities.
In the few instances where routine XR-NTX
treatment and placebo controlled trial were both
immediately available, patients elected the routine
treatment, suggesting that patients' preferences
may inﬂuence outcomes.
8) Naloxone in MA Routine overdose prevention education including intranasal
naloxone training and access was expanded in the HCCC
facilities and after incarceration program.
Overdose prevention and naloxone training was welcomed
by this population. Concerns about overdose if participants
were late for injections should include naloxone
prescription and availability.
9) Change in sentences from
Risk Reduction Earned
Credit program
Changes in policy changing the release date unexpectedly
for participants. Increased monitoring and communication
with the DOC was needed to ensure changes in a
participant's release date were known and interviews and
injections could be administered before he/she was
released. This change went into effect October 2011.
There was also a change in earned days from 5 to 10 in MA.
Communication with the DOC staff is essential to the
implementation and continuation of a study that
initiates in the correctional facility.
10) Reduction in the number
of HIV-infected inmates
Recruitment to those on parole or probation was expanded
in 2013 in an attempt to increase enrollment numbers.
With decreasing numbers in general inmate populations
and increase in various medication-assisted therapies for
HIV-infected inmates and alternative correctional
programs (halfway houses and drug programs),
alternative recruitment strategies are needed to capture
those involved in the criminal justice system.
Participant health
11) Required DSMB A DSMB was created with three board certiﬁed Infectious
Disease doctors at Yale to ensure the safety of the study
participants and study performance.
12) Education of overdose Education tools were developed to protect against overdose These educational sessions and tools, allowed to
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Table 3 (continued)
Obstacle Action taken Knowledge gained
risk at the end of the injection period and if a participant missed
an injection. This protocol contained a treatment agreement
and visual aid reviewed and signed by the participant
acknowledging the education received from the risk
education.
participants to fully understand the severity of the risk
to overdose and death if they should relapse. Treatment
agreements were used a treatment plans.
13) Relapse to opioid use To protect against withdrawal symptoms, should a
participant relapse to opioid use before his/her next
injection an extensive protocol was developed utilizing
self-reported opioid use, urine toxicology screen results,
an antagonist challenge and if needed a community
buprenorphine detoxiﬁcation.
These protocols have been modiﬁed for community
based administration of XR-NTX.
Legend: NIDA = National Institute on Drug Abuse; DOC = Department of Correction; CR = Clinical Researcher; CMHC = Correctional Managed Health Care; XR-
NTX = Extended-release naltrexone; HCCC = Hampton County Correctional Center; IRB = Internal Review Board; DSMB = Data Safety Management Board.
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of liver damage, pertinent medical history, review of
liver function tests (LFTs) and assessment of other
contraindications for XR-NTX including potential opioid
use, acute hepatitis, current prescription of opioidmedi-
cations, anticipated need for prescription opioid medi-
cations, pregnancy, and breastfeeding. Given that this
study is focused on opioid dependent individuals, some of
whom were receiving placebo, special attention was paid
to participants actively using opioids. We also showed
participants a time-dependent graph, provided by
Alkermes, Inc., to illustrate the risk of overdose given
the falling blood levels of XR-NTX. Participants then
signed a study agreement acknowledging their under-
standing of an increased risk of injury or death due to
opioid overdose if they did not receive their next injec-
tion at or around 4 weeks after the previous injection.
(5) Recent Opioid Use Protocol: All CRs were trained in the
study protocol that included extensive protections for
participants to avoid precipitating opioid withdrawal
(see Fig. 4). For participants actively using opioids
(within 7 previous days) but is not found to be physi-
cally dependent, s/he was given an antagonist (nalox-
one) challenge (0.4mg intramuscular) and if therewere
no signs of withdrawal in 10 minunites an additional
dose (0.8 mg) was administered. Opioid withdrawal
signs and symptoms are monitored using the Clinical
Opioid Withdrawal Scale (COWS) [53]. If the antagonist
challenge caused opioid withdrawal symptoms, partic-
ipants undergo a 5-day buprenorphine supervised
withdrawal protocol. If the antagonist challenge does
not precipitate withdrawal, the injection of the study
medication is administered if no other contradictions
were present. The community detoxification protocol
used was based on the Substance Abuse and Mental
Health Services Administration (SAMHSA) Tip 40 for a
5-day buprenorphine detox protocol (8 mg BID on day
1; 16 mg QD on day 2; 12 mg QD on day 3; 8 mg on day
4; and then 4mg on day 5) then off of buprenorphine for
3 to 5 days, with daily monitoring on the days off
buprenorphine. Upon completion of the supervised
withdrawal procedures, participants are then reassessed
for injection of the study medication.
(6) Counseling Visits: Irrespective of randomization during
the intervention phase (6 months post-release), as partof the 45-minute injection preparation process, all par-
ticipants receive a standardized monthly brief counsel-
ing intervention for opioid dependence, modified from
the Medical Management (MM) procedures used in the
COMIBINE trial for alcohol dependence [52,54,55]. This
modified 15-minute MM, conducted by the CR, reviews
medication and health information including opioid
pharmacotherapy, laboratory results, drug use and prior
counseling in addition to briefly counseling patients
about the hazards of using opioids. If participants were
perceived as failing the existing treatment program,
they were referred to more intensive community-based
counseling and/or treatment by our on-site substance
abuse counselors. In addition, all participants are offered
voluntary weekly 12-step counseling sessions held at all
of the study sites as well as individualized cognitive
behavioral counseling sessions by a licensed behavioral
health specialist [56–58]. Use of the voluntary cognitive
behavioral counseling interventions is monitored for
final study analysis.
7. Payments
Please refer to Table 1 for subject compensation. Partici-
pants were paid for contributing their time to the research
activities and not for receiving study medication. The form of
participant payment was changed from gift cards to cash in
2013 in response to patient preferences for payment.
8. Speciﬁc safety protocols
During the intervention phase of the study, participants are
monitored regularly for injection-related side effects, changes
in LFTs and renal function, and new contraindications to XR-
NTX including pregnancy and opioid relapse and withdrawal
[59]. Prior to administration of the study medication, the CR
reviews his/her current medications, medical diagnoses, labo-
ratory and drug urine screening results. If a participant de-
velops Grade 4 hepatotoxicity (defined as LFTs N10 times the
upper limit of normal with clinical symptoms or signs of hepa-
totoxicity), Child Pugh Class C cirrhosis, or becomes pregnant,
then injections are stopped and the participant is unblinded. As
an additional safety precaution, all participants' primary care
providers are sent letters confirming study enrollment, includ-
ing basic study information that the participant may be
Urine screen positive
for opioids† 
No
YesNo
Continue with clinical
protocol and give
injection if no other
contraindications are
present  **
Perform /refer to 5
day Suboxone detox*
Antagonist Challenge*
Tolerated?
Have client return 3 days
AFTER completing detox
to reassess and perform
antagonist challenge*
* If detox or antagonist (naloxone)
challenge are not available, client
returns in 5-7 days to reassess.
Assess for repeat drug use, if yes
reassess in 3-5 days.
Antagonist Challenge: administer
0.4 mg IM, observe 10 minutes;
administer 0.8 mg or 1.6 if urine
screen positive, observe 20
minutes
** If physically
dependent and <7 days
since opioid use, utilize
antagonist challenge or
reassess at day 7-10
after last opioid use
Daily use in past 7 days OR
anticipated withdrawal
Yes No
Is COWS score >4
Yes No
Urine screen positive
for opioids† 
NoYesYes
† methadone,
oxycodone,
buprenorphine,
or other opioids
Fig. 4. Clinical management of study participants and ongoing opioid use.
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of initial injection, possible side effects, a statement that opioid
pain medication should be avoided, and contact information
should s/he have any questions or concerns. Given that two
thirds of participants receive XR-NTX, safety wallet cards are
provided to all participants to give to any healthcare providers
should they require emergency pain medications in the setting
of a possible opioid antagonist effect fromXR-NTX and possible
requirements of pain medication during an emergency. For
individuals found to be actively using alcohol and/or drugs,
they are referred for additional community-based drug or
alcohol treatment.
9. Analytic plan
The analytic plan for this study is similar to another similarly
designed XR-NTX trial that focuses on pre-release prisoners
with HIV and alcohol use disorders [60]. Below is a brief de-
scription of the planned analysis.
9.1. HIV treatment outcomes
The primary study outcome is to compare the proportion of
participants achievingVSunder the threshold of b400 copies/mL
and b50 copies/mL at study month 6 (end of the intervention)
using chi-square tests and odds ratios with 95% confidence
intervals in the two groups. All participants that completed a
baseline interview are considered enrolled and followed for the
12 months, using an ITT analysis, all those with missing values
will be imputed as failure (noVS). The trial is on-going and thus
results are not currently known.Secondary HIV treatment outcomes include: mean change
in CD4 count and HIV-1 RNA level as a repeated measure at all
time points post-release. Changes in log10 HIV-1 RNA will be
fitted to a linear regression with interval censoring to account
for the large number of censored values owing to HIV-1 RNA at
the lower limits of detection at baseline and at follow-up.
Missing values will be imputed depending on whether values
meet missing at random assumptions. A general linear model
including baseline CD4 count and HIV-1 RNA as covariates will
assess mean change in the log10 CD4 count from baseline to
follow-up month 12.
Similarly, CD4 counts have been strongly associated with
survival and risk for development of opportunistic infections.
Therefore, it is the goal tomaintain or improve CD4 count. It will
not, however, be a primary endpoint as CD4 count benefits may
persist after loss of adherence. Analysis of change in mean/
median CD4 count frombaseline tomonths 6 and 12will use the
Wilcoxon rank test, stratified by variables such as cART expe-
rience. Spearman's rank correlation will test for associations
between a wide range of variables with a binomial distribution.
9.2. Substance abuse outcomes
Several drug relapse variables will be examined. The first
drug use variable will be “time to opioid relapse”. Subjects are
interviewed monthly using timeline followback (TLFB) [61].
Multiple variableswill be used to determine opioid use including
drug urine screens, positive naloxone challenge results, and the
TLFB method to ascertain the date of first use. Both a median
time-to-relapse will be calculated as well as Kaplan–Meier
time-to-event analysis performed. Significance will be tested
using the log rank test and Wilcoxon statistics. The second
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drug-free. Each month, a recall of days where illicit drugs were
used will be calculated from the TLFB method. For each
individual, a mean drug-free interval will be calculated. These
drug variables will be calculated for opioids, cocaine and for
“any” drug as an exploratory analysis. Last, the proportion of
positive drug urine screening results over the 6 months of the
intervention will be measured. Missing drug urine screen
results will be adjudicated in the following sequential manner:
1) self-report at monthly visits; and 2) last value carried
forward if no self-report was available and the next value was
the same as the previous one; 3) alternative strategies will
explore missing values as positive as well as imputing values
based on whether data are missing at random or not. The
percent of opioid-free urine screenings over the six-month
examination period will be compared between the two groups
after transforming outcome to means and compared statisti-
cally using Mantel–Haenszel Chi Square.
10. Implementation issues
When working with the CJS there are unique implementa-
tion and logistical concerns that were overcome during the
course of this study. Various concerns were addressed in a
similar study but were again encountered here [60]. Listed
below and in Table 3 are some of the additional barriers that
were encountered and overcome during this study.
• Review Board Protocol Approval: Multiple submissions to
the Yale IRB, Baystate Medical Center IRB, the Director of
Research at HCCC, CTDOC Research Advisory Committee, and
Waterbury Hospital IRB were required to ensure that each
facility was operating under the same systematic study
protocol, and to ensure that any and all issues were
addressed by the each institution. Although initial approval
from all of the review boards was approximately 6 months, a
total of 12 monthswas needed to coordinate the changes and
obtain final OHRP approval and a CoC (see Obstacle 4 in
Table 3).
• Data Safety Monitoring Board (DSMB): Per NIDA request, a
DSMB, expanded and more stringent than the original Data
Safety Monitoring Plan, was created which included three
board certified Infectious Disease doctors at Yale Medical
School to conduct interimmonitoring of the study's risk. Also
included in the DSMB was a protocol detailed with the pre-
cautions used in the study to monitor for side effects, liver
damage, risk of overdose, and other aspects of the study.
Responsibilities of the DSMB include reviewing the study
performance, evaluation of study quality, and recommending
the continuation of the ongoing study (see Obstacle 11 in
Table 3).
• Correctional Facility Information Sessions: Board-certified Ad-
diction Medicine physicians conducted information sessions
throughout the study regarding XR-NTX and other pharma-
cological treatments available in the community for those
with opioid dependence. These interactive sessions allowed
the correctional staff to learn about the differences in the
treatments, how they are administered, safety information,
and updates of treatment use. When this study was initiating
recruitment, XR-NTX was newly approved by the FDA for
opioid dependence; questions from the staff were expectedand addressed (see Obstacle 5 in Table 3).
• Coordination BetweenMultiple Sites: In order to ensure timely
and secure data transfer, a quarterly schedulewas created for
data transfers from Baystate Medical Center. Encrypted data
transfer systems provided by Yale University Information
Technology Services were used to ensure that participants'
information was protected in a HIPAA approved manor (see
Obstacles 2 and 3 in Table 3).
• Reduction of HIV-infected Inmate Population: During the study
submission process, the average daily census of HIV-infected
inmates in the CTDOC, where a majority of the participants
were recruited was 320 [62]. This number was substantially
reduced by 16.6% over the time of the study (personal
communication, C. Gallagher CTDOC, September 4, 2014) as a
consequence of several other projects that aimed to reduce
recidivism by providing other MAT for HIV-infected inmates
transitioning to the community (see Obstacle 10 in Table 3).
• Changes in Department of Correction Policy: At the end of 2011
and beginning of 2012 two major changes occurred in the
CTDOC policy. MMT was made available in one of the men's
jail facilities, the women's correctional facility in CT for those
with a short sentence and entered the facility while onMMT.
A pilot program in the Massachusetts drug and alcohol
rehabilitation facilities supervised by the HCCC began to offer
XR-NTX treatment. Additionally, those incarcerated with
specific non-violent charges were given the ability to earn
five days off of their sentence for each month of “good
behavior”with the Risk Reduction Earned Credit program. In
HCCC there was an increase in number of sentence reduction
days earned from 5 to 10 days (see Obstacles 6–9 in Table 3).
11. Summary
It is possible that the negative attitudes by correctional
providers, stigma, diversion concerns, poor adherence, and
additional restrictive licenses of using an opioid agonist for
treating opioid dependence may be possible reasons why they
are not widely deployed in the CJS [29,33,63]. XR-NTX provides
an alternative treatment as an opioid antagonist, which does
not require additional certifications or licenses to administer
and store these medications unlike agonist treatments [64,65].
The monthly dosing schedule of injections could potentially
reduce adherence concerns with daily oral medications and
eliminate the concerns of diversion. Additionally, the protective
properties of XR-NTX and the long-acting half-life may reduce
the risk of overdose upon release from the correctional system
when administered prior to release. Although other forms of
MAT are widely available in the U.S., including BMT, MMT, and
XR-NTX, no studies have compared these MATs for released
prisoners andMMTmust be initiated ~6 months pre-release in
order to achieve effective doses [66,67]. For most prisoners
who are not tolerant to opioids upon release, BMT and XR-NTX
are preferred options. Both medications, however, differ with
regard to pharmacology, route of administration (sublingual
versus injection), duration of effect (daily versus monthly),
benefits on alcohol disorders (XR-NTX) and opioid craving
(BMT), side effects, cost, impact on retention and patient
preferences. Moreover, prison administrators favor XR-NTX
over BMT due to its lack of dependence (“being addicted”), but
patients may reject it for other reasons. Thus comparative
effectiveness studies are urgently needed to inform patient-
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decision-making.
As part of the STTR model by NIDA, this is the first double-
bind, placebo-controlled clinical trial of XR-NTX for opioid
dependent, HIV-infected persons involved in the CJS. The novel
use of XR-NTX within the CJS as a conduit for HIV care will
strengthen the current evidence of the effectiveness of XR-NTX.
Concerns regarding hepatic safety of XR-NTX have been
expressed prior to initiating this intervention given the impact
of cART on liver function and the high rate of Hepatitis C virus
co-infection. New evidence, however, nowprovides assurances
of XR-NTX safety in HIV-infected patients on cART [68,69].
Given the consequences of relapse to opioid use after release
from the correctional system, XR-NTX can prevent relapse, and
prevent the spiral of poor care leading to increased HIV risk
behaviors, poor adherence to cART, and possible risk of
infecting those in the community.
Findings from this study may show the benefits of initiating
opioid treatment prior to release as a way to improve HIV treat-
ment by preventing and reducing drug use. Also of note, this
study provided an opportunity to develop a safety and clinical
protocol for the use of XR-NTX for opioid dependencewithin the
community including the monitoring of opioid relapse and
opioid withdrawal and use of a community detoxification pro-
tocol with buprenorphine prior to reinitiating injectionwith XR-
NTX that may be used by others in similar research settings or
for routine clinical use. Additionally, the preliminary findings of
acceptability for this form of opioid dependence treatment may
not be generalizable to all those involved in the CJS.
This studywas designed to provide good internal validity by
controlling known confounders, by having a target sample
powered to detect the difference in primary outcome using a
similar sample, using validated measurements, and by using
statistical methods that have been proven to reduce Type I and
Type II errors. The nature of this populationmay lead to a threat
to the external validity of this study as seen in the modest
acceptability of XR-NTX thus far in this on-going study. Given
the large number of thosewho refused at different stages of the
study there is a potential threat to the external validity of the
treatment and desire to enroll in the study. Unlike the initial
large clinical trial where other forms of MAT are not available
[70], a large percentage of the population (79%) reported a
previous experience with other forms of MAT and the main
reason for refusal was ‘the desire for treatment using another
form of MAT. This “choice” allows for the opportunity to
participate in an informed decision regarding their formofMAT
prior to release, which may reduce opioid relapse and the
negative consequences that occur from active drug use thereby
increasing the external validity of the study. With the recent
changes to the DSM-V and the availability of newer, office-
based treatments for opioid use disorders, we now require a
reassessment of transitional care for opioid dependent patients
in the CJS.
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